Key Opinion Leaders Share Insights on Advancing Wound Care
FRAMINGHAM, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical devices, announced today that it has launched its Experts in Wound Care Program, a series of interviews with key opinion leaders dedicated to advancing wound care.
The interviews will focus on important wound care topics, such as how evolving best practices can improve patient outcomes and lower overall healthcare costs and how AC5® Advanced Wound System is used during the management of chronic and acute wounds. Each event will be broadcast on the Company’s Experts in Wound Care video channel and can be tracked and tweeted by followers using the hashtag: #ExpertsInWoundCare.
In alignment with International Infection Prevention Week (October 17-23), the first interview in the Program, “A Novel Approach to Infection and Biofilm in Chronic Wounds”, is conducted with key opinion leader, Dr. Randall Wolcott, Founder of the Southwest Regional Wound Care Center in Lubbock, Texas. The interview with Dr. Wolcott is available at https://bit.ly/2YYMcOJ.
“Arch is proud to be affiliated with renowned experts in wound care, and we look forward to advancing the science of healing through the information presented in this program,” stated Terry Norchi, MD, Chief Executive Officer of Arch Therapeutics. “Our mission is to improve the lives of patients by providing products that enhance the quality of care offered by clinicians and mitigate the overall burden faced by healthcare institutions whenever challenging wounds are treated,” concluded Dr. Norchi.
About Arch Therapeutics, Inc.
Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma, and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch has received regulatory authorization to market AC5® Advanced Wound System and AC5 Topical Hemostat as medical devices in the United States and Europe, respectively. Arch's development stage product candidates include AC5-G, AC5-V and AC5 Surgical Hemostat, among others.1,2
Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our ability to recruit additional field sales representatives and their effectiveness, our business and product development plans and projections, or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to retain important members of our management team and attract other qualified personnel, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our ability to obtain required regulatory approvals, our ability to produce commercial quantities of our products within projected timeframes, our ability to obtain the inclusion of our AC5® Advanced Wound System on targeted federal supply schedules, our ability to develop and commercialize products based on our technology platform, and market conditions, and our ability to establish additional commercialization partnerships and build a critical mass of field sales representatives. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov.
Contact:
ARTH Investor Relations
Toll Free: +1-855-340-ARTH (2784) (US and Canada)
Email: investors@archtherapeutics.com
Website: www.archtherapeutics.com
or
Michael Abrams
Chief Financial Officer
Arch Therapeutics, Inc.
Phone: 617-431-2333
Email: mabrams@archtherapeutics.com
1 AC5-G, AC5-V, and AC5 Surgical Hemostat are currently investigational devices limited by law to investigational use.
2 AC5, AC5-G, AC5-V and associated logos are trademarks and/or registered trademarks of Arch Therapeutics, Inc. and/or its subsidiaries.
